Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AX Other antivirals
J05AX31 Lenacapavir
D12162 Lenacapavir sodium (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Agents, Other
Lenacapavir
D12162 Lenacapavir sodium (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D12162 Lenacapavir sodium (JAN/USAN)
Drug groups [BR:br08330]
Antiviral
DG03107 Anti-HIV agent
DG03165 Lenacapavir
D12162 Lenacapavir sodium
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG03165 Lenacapavir
D12162 Lenacapavir sodium
DG02924 UGT substrate
DG03183 UGT1A1 substrate
DG03165 Lenacapavir
D12162 Lenacapavir sodium
Transporter substrate
DG01665 ABCB1 substrate
DG03165 Lenacapavir
D12162 Lenacapavir sodium
Antimicrobials [BR:br08307]
Antivirals
Entry, fusion or uncoating inhibitor
HIV core protein inhibitor
D12162 Lenacapavir sodium (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D12162
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D12162
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D12162
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12162
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D12162
Drug transporters
D12162
Drug groups [BR:br08330]
Antiviral
DG03107 Anti-HIV agent
DG03165 Lenacapavir
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG03165 Lenacapavir
DG02924 UGT substrate
DG03183 UGT1A1 substrate
DG03165 Lenacapavir
Transporter substrate
DG01665 ABCB1 substrate
DG03165 Lenacapavir